HLDF-6

Modulates cholinergic neurotransmission. Reduces amyloid-β toxicity and protects against oxidative stress-induced neuronal damage. May enhance memory consolidation via acetylcholine pathway upregulation.

HLDF-6 (human leukemia differentiation factor hexapeptide; TGENHR) is a synthetic hexapeptide derived from a sequence of the HLDF protein, investigated in preclinical models for neuroprotective properties in conditions including Alzheimer's disease and Parkinson's disease, where it is proposed to reduce neuroinflammation, protect against beta-amyloid toxicity, and attenuate dopaminergic neuron loss. HLDF-6 is proposed to modulate inflammatory cytokines and oxidative stress pathways, with potential effects on acetylcholinesterase activity; preclinical animal studies in transgenic Alzheimer's models and MPTP-induced Parkinson's models suggest cognitive-protective properties at the cellular and behavioral level. No published human clinical trials, pharmacokinetic studies, or safety evaluations of HLDF-6 administration have been indexed in PubMed; the entirety of its evidence base consists of rodent and cell-based studies, and no regulatory authority has evaluated or approved HLDF-6 for any human indication. HLDF-6 has no FDA approval or regulatory approval in any jurisdiction; it is a neuroprotective research compound with a defined mechanistic hypothesis and an exclusively preclinical evidence base, and the translation of its animal model findings to human therapeutic outcomes has not been investigated.